Bimekizumab versus Adalimumab in Plaque Psoriasis

  • Griffith, Shantelle K. M.S.
  • Ahn, Grace S. B.S.
  • Wu, Jashin J. M.D.

  • 1Medical College of Georgia at Augusta University, Augusta, GA

    2University of California, San Diego, La Jolla, CA

    3Dermatology Research and Education Foundation, Irvine, CA [email protected]

Dr. Wu reports having been an investigator for AbbVie, Amgen, Eli Lilly, Janssen, and Novartis; a consultant for AbbVie, Almirall, Amgen, Arcutis Biotherapeutics, Aristea Therapeutics, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant Sciences, Dr. Reddy's Laboratories, Eli Lilly, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Regeneron, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, and Zerigo Health; and a speaker for AbbVie, Amgen, Bausch Health, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, and UCB. No other potential conflict of interest relevant to this letter was reported.

New England Journal of Medicine 385(12):p 1149-1150, September 16, 2021. | DOI: 10.1056/NEJMc2113092

Bimekizumab versus Adalimumab in Plaque Psoriasis

  • Warren, Richard B. M.D., Ph.D.
  • Blauvelt, Andrew M.D.
  • Bagel, Jerry M.D.
  • Papp, Kim A. M.D., Ph.D.
  • Yamauchi, Paul M.D., Ph.D.
  • Armstrong, April M.D., M.P.H.
  • Langley, Richard G. M.D.
  • Vanvoorden, Veerle M.Sc.
  • De Cuyper, Dirk M.D.
  • Cioffi, Christopher Ph.D.
  • Peterson, Luke M.S.
  • Cross, Nancy M.D.
  • Reich, Kristian M.D., Ph.D.
New England Journal of Medicine 385(2):p 130-141, July 8, 2021. | DOI: 10.1056/NEJMoa2102388
Copyright © 2021 Massachusetts Medical Society. All rights reserved.